Odds, Ends and Updates

Posted by: in Healthcare Insights, Public Relations Practice on February 17, 2011

Over the past few months, a number of the topics that have been touched on here at Common Sense have continued to evolve, and this time — during the traditional lull between the Super Bowl and the beginning of spring training — seems like a good time to highlight some of those updates:

  • J.P. Morgan: Yes, I wrote a whole blog post on how social media could never touch the impact of the in-person magic of the J.P. Morgan Health Care Conference but — as it turns out — this was a best-ever year for online discussion of the confab. The number tweets generated about the meeting more than doubled versus JPM10, coming at north of 1,000. That’s a lot of back-and-forth and a lot of commentary. It still can’t give you the claustrophobic sense of being at the meeting, but the hive mind did hit the highlights. (See my post-meeting J.P. Morgan Health Care overview at Pharmalot.)
  • The State of the Union (and the State of Innovation): Every year, right after the State of the Union, the president unveils his proposed budget. It is a purely symbolic document, generally DOA, but it is a way of measuring how seriously the White House takes certain issues. When I posted about the State of the Union address, I wondered aloud whether NIH would get what it needed. The Obama administration, as it turns out, is pushing for a 3.5 percent increase in the budget, barely keeping pace with inflation. But in these economic times, that would be something close to a victory.
  • Bad Health Information: The same week that I suggested the New York Times had it wrong in going after WebMD as a symbol of bad health information online, the Huffington Post, via Forbes, demonstrated that vetting by its “Medical Review Board” can be worse than no vetting at all.
  • FDA Social Media Rules: I outlined some myths about FDA rules at the end of last year, as we waited for guidelines to drop on how pharma could use social media tools. We’re still waiting. Bob’s post this week offers a different perspective on why the FDA in a tricky spot. The agency is apparently working on a 1Q deadline now, so look for this issue to re-emerge over the next 6 months.

By: Brian Reid

Brian Reid is a managing director at W2O Group, where he oversees influencer relations. He is a former journalist who believes content really is king.

Find me on: Twitter
Pre-Commerce Check out W2O Group President Bob Pearson's new book, Pre-Commerce, in which he shares ideas for leaders to engage directly with customers to shape their brand and marketplace success. Now available for order on Amazon.com! http://amzn.to/bAmvFN. Join the conversation #precommerce.

0 Responses

Stay in touch with the conversation, subscribe to the RSS feed for comments on this post.

Some HTML is OK


(required, but never shared)

or, reply to this post via trackback.